Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts